Will The Ghost Of TeGenero Stifle UK Biotech Innovation?
By Nuala Moran
Wednesday, May 30, 2007
LONDON - Members of the UK biotech industry met last week to discuss how they are coming to terms with the practical consequences of the disastrous TGN1412 clinical trial, and in particular the extra scrutiny to which biological products with novel modes of action are now subjected when moving into first-in-human trials. (BioWorld International)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.